Adverum Biotechnologies provides 2019 outlook

|About: Adverum Biotechnologies, Inc. (ADVM)|By:, SA News Editor

Adverum Biotechnologies (NASDAQ:ADVM) provides an outlook for 2019.

2019 Outlook - Planned Pipeline Milestones

ADVM-022 for wet AMD: Provide an update on enrollment from the OPTIC phase 1 clinical trial in H1 2019

Provide interim data on the three cohorts from the OPTIC phase 1 clinical trial by Q1 2020

Rare Disease Program: Provide an update preclinical development plan in H1 2019

Financial Guidance : Adverum’s cash, cash equivalents and marketable securities were $217.9M as of September 30, 2018. Adverum expects this quarter-end cash position to fund operations at least through H1 2020.


Subscribe for full text news in your inbox